Brief: Lundbeck And Otsuka Announce U.S. FDA's Approval Of SNDA For Rexulti® (Brexpiprazole) For The Treatment Of Dementia Due To Alzheimer's Disease

H Lundbeck A/S

11/05/2023 04:40

May 10 (Reuters) - H Lundbeck A/S  HLUNb.CO :
    * LUNDBECK AND OTSUKA ANNOUNCE U.S. FOOD AND DRUG
ADMINISTRATION
(FDA) APPROVAL OF SNDA FOR REXULTI® (BREXPIPRAZOLE) FOR THE
TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO
ALZHEIMER'S DISEASE

Source text for Eikon:  ID:nWkr86mm7Q 
Further company coverage:  HLUNb.CO 

 ((Reuters.Briefs@thomsonreuters.com;))